Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2289 (LINC02289) is a long intergenic non-protein coding RNA (lincRNA), meaning it is an autonomously transcribed RNA molecule longer than 200 nucleotides that does not overlap with protein-coding genes[1][5][7]. LINC02289 does not encode a protein and, as with the majority of lincRNAs, its specific biological functions have not been fully elucidated. Generally, lincRNAs are a subset of long non-coding RNAs that can perform regulatory roles, such as modulating chromatin structure, stabilizing RNAs, and regulating the transcription of coding or non-coding genes, sometimes via enhancer-like activities[3]. While some lincRNAs have been functionally implicated in cell proliferation, cell cycle regulation, chromatin modulation, or disease phenotypes, there is currently no evidence that LINC02289 serves as a therapeutic target, is directly associated with drugs, or acts as a biomarker for patient selection or efficacy monitoring[1][5][7].
Not applicable (no drugs known to directly target LINC02289)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2289 (LINC02289).